The goal of the present study was to test the effect of low-dose ASA on the progression of vessel wall remodelling, atherosclerosis, and cardiovascular complications in apolipoprotein E deficient (ApoE−/−) mice, the classical model to study atherosclerosis, and ApoE−/− mice with a heterozygous mutation in the fibrillin-1 gene (Fbn1C1039G+/−). The gene discussed is FBN1; the disease is atherosclerosis.